article has not abstract
Linked Policy Forum
This Perspective discusses the following new Policy Forum published in PLoS Medicine:
Doshi P, Jefferson T, Del Mar C (2012) The Imperative to Share Clinical Study Reports: Recommendations from the Tamiflu Experience. PLoS Med 9(4): e1001201. doi:10.1371/journal.pmed.1001201
Peter Doshi and colleagues describe their experience trying and failing to access clinical study reports from the manufacturer of Tamiflu and challenge industry to defend their current position of RCT data secrecy.
In this issue of PLoS Medicine, Doshi and colleagues argue that the full clinical trial reports of authorized drugs should be made publicly available to enable independent re-analysis of drugs' benefits and risks . We offer comments on their call for openness from a European Union drug regulatory perspective.
For the purpose of this discussion, we consider “clinical study reports” to comprise not just the protocol, summary tables, and figures of (mostly) randomized controlled trials (RCTs), but the full “raw” data set, including data at the patient level . We limit discussion to data on drugs for which the regulatory benefit-risk assessment has been completed.
Why Trial Data Should Be Open for All
First and foremost, we agree with Doshi et al. that clinical trial data should not be considered commercial confidential information; most patients enrolling in clinical trials do so with an assumption of contributing to medical knowledge, and “non-disclosure of complete trial results undermines the philanthropy” .
The potential benefits for public health of independent (re-)analysis of data are not disputed and, in an open society, trial sponsors and regulators do not have a monopoly on analyzing and assessing drug trial results. Yet, the different responsibilities of regulators and independent analysts have to be acknowledged. Regulators, unlike academicians, are legally obliged to take timely decisions on the availability of drugs for patients, even under conditions of uncertainty.
Going beyond the merits of independent meta-analysis, we foresee other, potentially more important benefits from public disclosure of raw trial data. For example, RCT datasets enabled the development of predictive models for patient selection to appropriate treatments ,. Taking this notion a step further, we envisage machine learning systems that will allow clinicians to match a patient's electronic health record directly to RCT and observational study data sets for better, individualized therapeutic decisions (L. Perez-Breva, personal communication).
Large, information-rich datasets are needed to support the computer science and artificial intelligence research required to develop and test these applications. Developing such tools is usually not a priority for, and often beyond the capabilities and resources of, even the largest pharmaceutical companies. These endeavors might best thrive in an environment that invites research from beyond the current stakeholders in health . Making rich datasets available for research is a means to open health research.
Why Trial Data Should Not Be Open for All
There are indeed many good arguments for unrestricted and easy access to full RCT data. Yet, simply uploading all trial data on a website would entail its own problems.
First among those is the issue of personal data protection or patient confidentiality, a concept that is very different from commercial confidentiality. There is a small risk that personal data could inadvertently be publicized. There is also a small risk that an individual patient could be identified from an anonymized dataset, for example, from trials in ultra-rare diseases. Achieving an adequate standard of personal data protection is not an insurmountable obstacle, though, and proposals for best practice for publishing raw data are available . However, implementation is not straightforward, standards will need to be agreed upon up front, and data redaction may in a few cases be resource intensive.
Our second caveat is likely more contentious. We do not dispute that financial conflicts of interests (CoIs) may render analyses and conclusions “vulnerable to distortion” . However, surrounding the ongoing debate over sponsor-independent analyses is an implicit assumption that “analysis by independent groups” is somehow free from CoIs. We beg to differ. Personal advancement in academia, confirmation of previously defended positions, or simply raising one's own visibility within the scientific community may be powerful motivators. In a publish-or-perish environment, would the finding of an important adverse or favorable drug effect at the p<0.05-level be more helpful to a researcher than not finding any new effects? Will society always be guaranteed that a finding that is reported as “confirmatory” was not the result of multiple exploratory re-runs of a dataset? We submit that analyses by sponsor-independent scientists are not generated in a CoI-free zone and, more often than not, ego trumps money. Independent analyses may therefore also be “vulnerable to distortion”. We are concerned that unrestricted availability of full datasets may in some cases facilitate the publication of papers containing misleading results, which in turn lead to urgent calls for regulatory action. In a worst case, this would give rise to unfounded health scares with negative public health consequences such as patients refusing vaccinations or discontinuing drug treatment ,.
Aside from CoIs, independent analysis per se is no guarantee of high quality. The regulatory community has been confronted with meta-analyses that were later contradicted by additional evidence  or found to be flawed . We argue that independent analyses warrant a similar level of scrutiny as sponsor-conducted analyses do.
Finally, re-analysis of trial data could be misused for competitive purposes.
The Way Forward?
We consider it neither desirable nor realistic to maintain the status quo of limited availability of regulatory trials data. What is needed is a three-pronged approach:
Develop and agree upon adequate standards for protection of personal data when publicizing RCT datasets. Most stakeholders will likely agree that adequate standards of data protection are a sine qua non, so the issue should be primarily of a technical and legal nature. We emphasize adequate standards because excessive demands and unrealistically high standards may in effect become an “anti-commons” and frustrate important public health gains.
Ensure general adoption of established quality standards of meta-analyses and other types of (confirmatory) data re-analysis that may warrant regulatory action.
Establish rules of engagement: In the area of observational studies based on health care databases, the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) has recently published guidance for raw data sharing; these rules of engagement follow the principle of maximum transparency whilst respecting the need to guarantee data privacy and to avert the potential for misuse . Others have come up with broadly similar proposals . Conceivably, analogous principles (e.g., data sharing only after receipt of a full analysis plan) could be applied to regulatory RCT data .
Moreover, we take it as self-evident that the same standard of openness should apply to all (drug) trial data, whether sponsored by industry, investigator-initiated, or sponsored by public grant-giving bodies. Likewise, the same standard of third party scrutiny should be applicable to all secondary data analyses. Regulatory inspections of data and analyses carried out by commercial sponsors are routine. Would all sponsor-independent researchers allow the same level of inspections applied to their analyses?
We welcome debate on these issues, and remain confident that satisfactory solutions can be found to make complete trial data available in a way that will be in the best interest of public health.
1. DoshiPJeffersonTDel MarC 2012 The imperative to share clinical study reports. PLoS Med 9
2. HrynaszkiewiczIAltmanDG 2009 Towards agreement on best practice for publishing raw clinical trial data. Trials 10 17 Available: http://www.trialsjournal.com/content/10/1/17. Accessed 9 March 2012
3. SelkerHPRuthazerRTerrinNGriffithJLConcannonT 2011 Random treatment assignment using mathematical equipoise for comparative effectiveness trials. Clin Transl Sci 4 1 10 16
4. KentDMHaywardRAGriffithJLVijanSBeshanskyJR 2002 An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase. Am J Med 113 2 104 111
5. NielsenM 2012 Reinventing discovery: the new era of networked science Princeton and Oxford Princeton University Press
6. PolandGAJacobsonRM 2011 The age-old struggle against the antivaccinationists. N Engl J Med 364 97 99
7. LofstedtRBouderFChakrabortyS 2012 Transparency and the FDA – a quantitative study. J Health Communications In press
8. MicheleTMPinheiroSIyasuS 2010 The safety of tiotropium — the FDA's conclusions. N Engl J Med 363 1097 1099
9. European Medicines Agency 2011 Questions and answers on the review of angiotensin II receptor antagonists and the risk of cancer. Available: http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2011/10/WC500116862.pdf. Accessed 9 March 2012
10. European Network of Centres for Pharmacoepidemiology and Pharmacovigilance 2011 The ENCePP Code of Conduct for Scientific Independence and Transparency in the Conduct of Pharmacoepidemiological and Pharmacovigilance Studies. Available: http://www.encepp.eu/code_of_conduct/documents/CodeofConduct_Rev2.pdf. Accessed 9 March 2012
11. YoungSSKarrA 2011 Deming, data and observational studies. Significance 8 3 116 120